These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 11926717)

  • 41. Escitalopram in the long-term treatment of major depressive disorder in elderly patients.
    Kasper S; Lemming OM; de Swart H
    Neuropsychobiology; 2006; 54(3):152-9. PubMed ID: 17230032
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
    Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
    J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acute antidepressive efficacy of lithium monotherapy, not citalopram, depends on recurrent course of depression.
    Bschor T; Uhr M; Baethge C; Lewitzka U; Ising M; Erbe S; Winkelmann P; Ritter D
    J Clin Psychopharmacol; 2013 Feb; 33(1):38-44. PubMed ID: 23277245
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.
    Mao PX; Tang YL; Jiang F; Shu L; Gu X; Li M; Qian M; Ma C; Mitchell PB; Cai ZJ
    Depress Anxiety; 2008; 25(1):46-54. PubMed ID: 17149753
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial.
    Lespérance F; Frasure-Smith N; Koszycki D; Laliberté MA; van Zyl LT; Baker B; Swenson JR; Ghatavi K; Abramson BL; Dorian P; Guertin MC;
    JAMA; 2007 Jan; 297(4):367-79. PubMed ID: 17244833
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial.
    McElroy SL; Hudson JI; Malhotra S; Welge JA; Nelson EB; Keck PE
    J Clin Psychiatry; 2003 Jul; 64(7):807-13. PubMed ID: 12934982
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomized controlled trial of antidepressant continuation for major depression following traumatic brain injury.
    Rapoport MJ; Mitchell RA; McCullagh S; Herrmann N; Chan F; Kiss A; Feinstein A; Lanctôt KL
    J Clin Psychiatry; 2010 Sep; 71(9):1125-30. PubMed ID: 20441723
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial.
    Bech P; Fava M; Trivedi MH; Wisniewski SR; Rush AJ
    Acta Psychiatr Scand; 2012 Apr; 125(4):342-8. PubMed ID: 22077211
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sexual function during bupropion or paroxetine treatment of major depressive disorder.
    Kennedy SH; Fulton KA; Bagby RM; Greene AL; Cohen NL; Rafi-Tari S
    Can J Psychiatry; 2006 Mar; 51(4):234-42. PubMed ID: 16629348
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Does negative affectivity predict differential response to an SSRI versus a non-SSRI antidepressant?
    Gerra ML; Marchesi C; Amat JA; Blier P; Hellerstein DJ; Stewart JW
    J Clin Psychiatry; 2014 Sep; 75(9):e939-44. PubMed ID: 25295437
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Citalopram treatment of paroxetine-intolerant depressed patients.
    Thase ME; Ferguson JM; Lydiard RB; Wilcox CS
    Depress Anxiety; 2002; 16(3):128-33. PubMed ID: 12415538
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fluoxetine versus placebo in posttraumatic stress disorder.
    Martenyi F; Brown EB; Zhang H; Prakash A; Koke SC
    J Clin Psychiatry; 2002 Mar; 63(3):199-206. PubMed ID: 11926718
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
    Brown ES; Howard C; Khan DA; Carmody TJ
    Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
    Kennedy SH; Andersen HF; Lam RW
    J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bupropion in the treatment of outpatients with asthma and major depressive disorder.
    Brown ES; Vornik LA; Khan DA; Rush AJ
    Int J Psychiatry Med; 2007; 37(1):23-8. PubMed ID: 17645195
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response.
    Wade AG; Crawford GM; Nemeroff CB; Schatzberg AF; Schlaepfer T; McConnachie A; Haazen L; Buntinx E
    Psychol Med; 2011 Oct; 41(10):2089-97. PubMed ID: 21349239
    [TBL] [Abstract][Full Text] [Related]  

  • 57. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?
    Bandelow B; Baldwin DS; Dolberg OT; Andersen HF; Stein DJ
    J Clin Psychiatry; 2006 Sep; 67(9):1428-34. PubMed ID: 17017830
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report.
    Gilmer WS; Gollan JK; Wisniewski SR; Howland RH; Trivedi MH; Miyahara S; Fleck J; Thase ME; Alpert JE; Nierenberg AA; Warden D; Fava M; Rush AJ
    J Clin Psychiatry; 2008 Aug; 69(8):1246-56. PubMed ID: 18681756
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors.
    Landén M; Eriksson E; Agren H; Fahlén T
    J Clin Psychopharmacol; 1999 Jun; 19(3):268-71. PubMed ID: 10350034
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid major depression or dysthymia: effectiveness, tolerability and predictors of response.
    Perugi G; Frare F; Toni C; Ruffolo G; Torti C
    Neuropsychobiology; 2002; 46(3):145-9. PubMed ID: 12422062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.